FDA Grants Breakthrough Therapy Designation To Investigational Maternal Vaccine For GBS Prevention In Infants

Infectious Disease Advisor (9/9, Park) reported the FDA “has granted Breakthrough Therapy designation to an investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 (hexavalent anti capsular polysaccharide/cross reactive material 197 glycoconju...